CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 290 enrolled
Drug / intervention
Pleiotropic info, in-person disclosure +3 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00462917
NCT00462917N/ACompleted
CompareCT.gov

Risk Evaluation and Education for Alzheimer's Disease

Brigham and Women's Hospital·interventional·Posted Apr 19, 2007·Updated Oct 23, 2018

In Brief

A clinical study evaluating Pleiotropic info, in-person disclosure, AD-only info, in-person disclosure, and 2 other interventions for Alzheimer Disease. Completed, enrolled 290 participants across 4 sites.

Detailed Summary

The purpose of this study is to provide healthy adults with genetic testing and information about their chances of developing Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsNational Human Genome Research Institute (NHGRI)

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 19, 2007
Enrollment StartMar 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.2 years ago

Interventions

Pleiotropic info, in-person disclosurebehavioral

Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information. Genetic counselors communicate results to participants during an in-person disclosure session.

AD-only info, in-person disclosurebehavioral

Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping. Genetic counselors communicate results to participants during an in-person disclosure session.

Pleiotropic info, phone disclosurebehavioral

Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information. Genetic counselors communicate results to participants during a telephone disclosure session.

AD-only info, phone disclosurebehavioral

Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping. Genetic counselors communicate results to participants during an in-person disclosure session.